Aurora Cannabis

Aurora’s moat relies on regulatory and operational intangibles rather than consumer brand power. The company operates EU‑GMP certified facilities and uniquely manufactures domestically in Germany at Leuna, which, together with Canadian GMP capacity, supports compliant, reliable supply across regulated markets.

This provides barriers to entry in markets that require GMP certification and controlled import channels. Still, these are not impenetrable: EU‑GMP certification is attainable by well‑capitalized rivals, and Germany’s liberalization plus growing imports imply intensifying competition over time.

Switching costs for prescribers and patients are modest, with partial stickiness from insurance formularies and consistent quality, but not enough to be durable on their own. We see limited cost advantage beyond scale procurement and manufacturing learning effects.

Efficient scale exists in select export markets with quota or license constraints, but those protections may erode as more suppliers qualify. Overall, we credit modest, execution‑dependent advantages rather than a thick, enduring moat.

Adjusted gross margins of 69% in medical (62% consolidated) indicate some pricing power today, driven by regulated medical channels, insurance coverage and high‑quality EU‑GMP supply. However, this appears more a function of mix and regulatory friction than intrinsic, defendable pricing power.

As more EU‑GMP players scale into Germany, Poland, the UK and Australia, price competition could increase, and payors may push back on reimbursement levels. Aurora’s pivot away from the Canadian consumer segment, where price compression has been severe, helps preserve margin structure but does not eliminate competitive risk abroad.

Net: modest to fair pricing power while the market remains constrained, with downside risk as the field broadens.

The business mix skews to recurring medical demand, which should be steadier than adult‑use, yet quarterly results remain volatile due to export timing, tenders, and working‑capital swings. FY2026 illustrates this: Q1 free cash flow positive, Q2 deeply negative on working capital and seasonal items, then Q3 positive again.

Regulatory change is an additional source of variance, particularly in Europe. We expect long‑term growth in medical volumes, but the cadence will likely be uneven, making multi‑year cash flow less predictable than in classic toll‑booth businesses.

Liquidity is solid with about CAD 154.4 million in cash, restricted cash and short‑term investments as of December 31, 2025; the cannabis business carries no recourse debt, though Bevo has roughly CAD 62 million non‑recourse debt.

The company has also filed a US$100 million ATM facility, which enhances financing flexibility but raises dilution risk. On profitability, adjusted EBITDA is positive and margins are improving, yet TTM free cash flow is still negative and there are material weaknesses in internal controls per the FY2025 audit.

We see low near‑term insolvency risk, but quality investors should demand consistent positive FCF and internal‑control remediation before assigning a stronger score.

Historical capital allocation destroyed value via overbuilt capacity and acquisitions that led to large impairments.

Recent moves are more disciplined: a strategic focus on high‑margin medical, exit of certain Canadian consumer markets, and a pending Bevo transaction to deconsolidate plant propagation in exchange for preferred shares, dividends and a share of cash flows.

However, reliance on non‑GAAP metrics, recurring “business transformation” adjustments, and launching a sizable ATM limit our enthusiasm. Until the company demonstrates sustained positive TTM FCF and refrains from equity issuance except for truly accretive uses, we judge capital allocation as below average.

Leadership under CEO Miguel Martin has executed the medical pivot and restored positive adjusted EBITDA, while CFO Simona King communicates a pathway to cash generation. That said, material weaknesses in internal controls flagged in FY2025 and continued dependence on non‑GAAP adjustments weigh on our assessment.

Execution quality looks improved versus 2020–2022, but trust must be rebuilt with sustained clean audits, consistent FCF and limited dilution.